A Denver shunt is a small, implantable device that drains excess fluid from the abdomen or chest cavity into a large vein, returning it to the bloodstream. It was developed as an improvement on the earlier LeVeen shunt, and its distinguishing feature is a manually compressible pump that sits just under the skin. The device is used primarily for people with refractory ascites, meaning fluid buildup that keeps coming back despite medications and repeated drainage, whether from advanced liver disease or widespread cancer. Although alternatives like TIPS have overtaken it in many liver-disease scenarios, the Denver shunt remains a meaningful option when those alternatives are not feasible.
How the Device Works
The Denver shunt is a long silicone catheter with a one-way pressure valve and a subcutaneous pumping chamber. One end of the catheter sits in the peritoneal cavity (the space around your abdominal organs where ascites collects), and the other end threads through a tunnel under the skin into the internal jugular vein or the superior vena cava, a large vein near the heart. When pressure in the abdomen exceeds the pressure in the venous system, the valve opens and fluid flows from the belly into the bloodstream. The pump chamber, which the patient or a caregiver can press through the skin several times a day, helps flush the catheter and keep it from clogging. This is the key design difference from the older LeVeen shunt, which lacked a pump and had no external way to clear debris.
The same basic catheter can be routed from the pleural space (around the lungs) rather than the peritoneum. In that configuration it is sometimes called a pleurovenous shunt and drains persistent pleural effusions. Reported complications of both configurations include shunt failure, pulmonary edema, coagulopathy, deep vein thrombosis, infection, and, rarely, catheter leaks at connection sites.1PubMed Central. Complications of Denver Shunt
Refractory Ascites from Liver Cirrhosis
The most common reason someone gets a Denver shunt is refractory ascites caused by advanced cirrhosis. When the liver is severely scarred, pressure builds in the portal venous system and fluid weeps into the abdomen faster than the body can reabsorb it. Diuretics are the first line of defense, but roughly one in ten cirrhosis patients reaches a point where diuretics no longer work or cause unacceptable side effects like kidney failure. At that stage, the fluid has to be removed physically, and repeated large-volume paracentesis (draining liters at a time through a needle) becomes a regular event, sometimes every week or two.
A Denver shunt can break that cycle. The device continuously returns ascitic fluid to the circulation, which controls the fluid buildup, reduces dependence on frequent drainage, and helps preserve kidney function and serum protein levels.2American Journal of Roentgenology (AJR). Percutaneous placement and management of the Denver shunt for portal hypertensive ascites A recent single-center study of patients with decompensated cirrhosis reported a mean shunt patency of about 345 days and median survival of roughly 474 days after placement.3PubMed Central. Chronological Course and Clinical Features after Denver Peritoneovenous Shunt Placement in Decompensated Liver Cirrhosis In a broader retrospective study covering both malignant and cirrhotic refractory ascites over more than two decades, Denver shunt placement met efficacy criteria for ascites control in about 68% of patients overall.4PubMed Central. Biomarker-guided strategy for Denver peritoneovenous shunts in refractory ascites: a retrospective single-center study
Those numbers reflect the reality that shunt patency is not permanent. Clotting, fibrin buildup, and protein deposits gradually narrow or block the catheter. Patients who pump the chamber regularly tend to get longer service from their shunts, but eventual occlusion is common and sometimes requires revision or replacement.
Palliative Use in Malignant Ascites
Cancer that spreads through the abdomen, especially ovarian, gastric, colorectal, and pancreatic cancers, often causes massive ascites in its later stages. For these patients the goal is comfort, not cure, and a Denver shunt can meaningfully reduce the burden of symptoms and hospital visits. In one study focused entirely on malignant refractory ascites, relief of ascites symptoms was achieved in about 88% of cases, with patients reporting less shortness of breath, improved appetite, and better ability to walk.5PubMed. Palliative treatment of malignant refractory ascites by positioning of Denver peritoneovenous shunt
A multicenter retrospective study from Japan found that shunts were effective, meaning symptoms improved for at least seven days, in about 83% of patients. But median survival in this cancer population was only 41 days, and the median duration of symptom relief was 26 days.6PubMed. Radiological insertion of Denver peritoneovenous shunts for malignant refractory ascites: a retrospective multicenter study (JIVROSG-0809) A smaller series similarly found that five of eight shunts provided excellent palliation, though subclinical coagulopathy, a mild disruption of blood clotting that did not cause overt bleeding, was detected after six of the eight placements.7PubMed Central. Palliation of malignant ascites by the Denver peritoneovenous shunt
The short survival figures are a reflection of the underlying disease, not the device itself. Even a few weeks free of the discomfort and repeated hospital trips that come with serial paracentesis can matter enormously to someone in the final months of life.
How It Compares to TIPS
For cirrhotic patients specifically, the main procedural alternative is a transjugular intrahepatic portosystemic shunt, or TIPS. Instead of moving fluid from the belly into a vein, TIPS creates a channel inside the liver that connects the high-pressure portal vein to a lower-pressure hepatic vein, attacking the root cause of the fluid buildup rather than just draining the result. The two approaches have been compared head to head in a prospective randomized trial.
That trial found that initial shunt patency was similar between the two devices: about four months median for both. But assisted patency, meaning patency after interventions to reopen blocked shunts, strongly favored TIPS at roughly 31 months versus 13 months for peritoneovenous shunts. Survival also trended in favor of TIPS, at about 29 months median compared with 16 months. Ascites control was actually faster with the peritoneovenous shunt (73% had control at one month, versus 46% for TIPS), but by three years the longer-term efficacy of TIPS was clearly superior, with about 85% of TIPS patients still controlling their ascites compared with 40% in the peritoneovenous shunt group.8PubMed Central. TIPS Versus Peritoneovenous Shunt in the Treatment of Medically Intractable Ascites A Prospective Randomized Trial
Given these results, TIPS has become the preferred interventional approach for refractory ascites in cirrhosis when a patient’s liver function can tolerate it. The Denver shunt still fills a gap for patients who are not candidates for TIPS because of portal vein thrombosis, very advanced liver failure where TIPS risks precipitating hepatic encephalopathy, or malignant ascites where the portal hypertension mechanism does not apply.
Complications Worth Knowing About
The Denver shunt’s complication profile is one of the main reasons it fell out of routine use. Problems fall into a few categories, some predictable and manageable, others more serious.
- Shunt occlusion: The most common reason for shunt failure. Fibrin, protein debris, and blood products gradually coat the valve or block the catheter. Regular pumping helps, but many shunts eventually clog and need revision or replacement.
- DIC (disseminated intravascular coagulation): When ascitic fluid enters the bloodstream, substances in that fluid can trigger a dangerous clotting cascade. DIC has been reported in roughly 5% of cases within the first week after placement.9Case Reports in Oncology. Reinfusion of Malignant Ascites through an Extracorporeal Peritoneal Venous Shunt to Avoid Complications and Assess the Safety of a Denver Shunt: A Case Report The risk appears to be higher with malignant ascites, particularly when the fluid is bloody. Some centers have experimented with replacing the ascites with saline before shunt placement to dilute clot-triggering substances, though this approach has practical drawbacks like abdominal bloating.
- Fluid overload and pulmonary edema: In the early period after placement, the sudden return of large volumes of fluid to the circulation can overwhelm the heart and lungs, causing pulmonary edema or respiratory distress.10PubMed Central. Complications of Denver Shunt Patients with pre-existing heart failure are at particularly high risk.
- Infection: Any implanted device carries infection risk. Prophylactic antibiotics and wound irrigation during placement have helped reduce rates, but shunt infection, when it occurs, typically requires device removal.
- Rare catheter problems: Leaks at connection points, catheter migration, and erosion into surrounding tissue have all been described in case reports. One unusual case involved a leak at the venous end of the catheter that created a large fluid collection in the neck.
Monitoring in the first week after placement is especially important. Rising D-dimer levels can be an early warning sign of DIC or thrombotic complications. One study noted that a patient with continuously rising D-dimer levels at two and seven days after placement developed renal and splenic infarction from thrombotic disease.11PubMed Central. Chronological Course and Clinical Features after Denver Peritoneovenous Shunt Placement in Decompensated Liver Cirrhosis
Denver Versus LeVeen
The Denver shunt was designed as a second-generation peritoneovenous shunt, adding the compressible pump to address the LeVeen shunt’s tendency to clog. Somewhat counterintuitively, at least one randomized trial in cirrhotic patients found that the LeVeen shunt actually had superior patency compared with the Denver shunt, while survival was similar between the two. That trial concluded the LeVeen was preferred for cirrhotic ascites specifically.12PubMed. LeVeen vs Denver peritoneovenous shunts for intractable ascites of cirrhosis. A randomized, prospective trial
The picture changes with chylous ascites, a milky fluid caused by lymphatic disruption. A series comparing the two shunt types specifically for refractory chylous ascites found a stark difference in the opposite direction from what you might expect: median patency was 215 days for the LeVeen shunt but only 44 days for the Denver shunt, and all six patients with Denver shunts eventually required shunt replacement.13PubMed. Management of refractory chylous ascites with peritoneovenous shunts The thick, protein-rich nature of chylous fluid may contribute to more rapid clogging of the Denver’s valve mechanism.
In practice, LeVeen shunts have been largely discontinued from the market in many countries, leaving the Denver shunt as the most widely available peritoneovenous shunt option. Review-level evidence from the post-LeVeen era has found that outcomes with the Denver shunt are not significantly different from historical results reported for both shunt types combined.
Less Common Uses
Chylous Ascites After Surgery
Chylous ascites sometimes develops after abdominal surgery, particularly operations involving extensive lymph node dissection near the liver, pancreas, or retroperitoneum. When dietary changes (low-fat diets, medium-chain triglycerides) and medications like octreotide fail to resolve the fluid collection, a peritoneovenous shunt can serve as a salvage procedure. One case report described an 80-year-old man who developed massive chylous ascites and pleural effusion after extended liver resection for cholangiocarcinoma. After conservative management failed, peritoneovenous shunting resolved his symptoms without major adverse events aside from a transient fever.14PubMed Central. Peritoneovenous Shunting to Manage Chylous Ascites Following Liver Resection for Cholangiocarcinoma: A Case Report
Pediatric Patients
Congenital chylous ascites in infants is rare but can be life-threatening when the fluid accumulation compresses the lungs and impairs breathing. When conservative management with diuretics, dietary modifications, and repeated paracentesis does not relieve respiratory distress, a peritoneovenous shunt has been used as a bridge to give the lymphatic system time to mature. Clinicians have noted, however, that shunts in infants with generalized lymphatic malformations may not maintain the same long-term function seen in adults with cirrhotic ascites, likely because the underlying lymphatic abnormality continues to produce unusually high volumes or types of fluid that challenge the device’s durability.15PubMed. Experience with peritoneo-venous shunting for congenital chylous ascites in infants and children
What Happens When a Denver Shunt Clots
Given how frequently these shunts occlude, the question of what to do about a blocked device comes up regularly. The standard approach has been surgical revision, either replacing the clogged catheter segment or implanting an entirely new shunt. But some centers have tried a less invasive approach: injecting a clot-dissolving drug directly into the shunt’s pump chamber to break up the obstruction in place.
One early report described using urokinase to lyse clots in a Denver shunt on three separate occasions in a single patient, preserving shunt function over a two-year period. The third procedure, unfortunately, resulted in a fatal complication, which tempered enthusiasm for the technique while still suggesting it could be a reasonable first attempt before committing to surgical revision in some patients.16Journal of Vascular and Interventional Radiology. Urokinase therapy for thrombosed Denver peritoneovenous shunts The approach has not been widely adopted, partly because of limited data and partly because many patients who need shunt revision are already poor surgical or procedural candidates.
Interventional radiologists have increasingly taken over placement and management of these devices. Rather than the open surgical implantation that was standard in the 1980s and 1990s, modern Denver shunts can be placed percutaneously under imaging guidance, which reduces recovery time and allows the procedure in patients who would not tolerate general anesthesia and a full surgical operation.17American Journal of Roentgenology (AJR). Percutaneous placement and management of the Denver shunt for portal hypertensive ascites
Patient Selection and the Role of Biomarkers
One of the persistent challenges with peritoneovenous shunts is figuring out which patients will actually benefit. A shunt that clots within weeks, triggers DIC, or gets placed in someone who dies of their underlying disease before getting meaningful symptom relief is not a success, even if it was technically inserted correctly. The 68% efficacy rate in the large retrospective study mentioned earlier means roughly a third of patients did not achieve adequate ascites control, which is a substantial failure rate for an invasive procedure.18PubMed Central. Biomarker-guided strategy for Denver peritoneovenous shunts in refractory ascites: a retrospective single-center study
Recent work has explored whether blood biomarkers can help predict which patients will respond well. The idea is to identify markers of coagulation, inflammation, or liver function that correlate with shunt patency and clinical improvement, steering the device toward patients most likely to benefit and away from those whose fluid characteristics make early clogging or DIC probable. This kind of biomarker-guided patient selection is still being refined, but it represents a shift from the earlier approach of offering shunts broadly to anyone with refractory ascites.
For malignant ascites, the selection calculus is different. Since median survival is often measured in weeks, the threshold for “benefit” is lower: even a month without needing to come in for drainage can be worthwhile. Bloody or heavily proteinaceous ascites, on the other hand, raises the risk of both clogging and DIC, making the shunt a less attractive option.19Case Reports in Oncology. Reinfusion of Malignant Ascites through an Extracorporeal Peritoneal Venous Shunt to Avoid Complications and Assess the Safety of a Denver Shunt: A Case Report Some teams have experimented with extracorporeal reinfusion circuits, essentially running the ascitic fluid through the shunt very slowly outside the body first, to test whether DIC-triggering substances are present before committing to a permanent implant. Early case-level evidence suggests that slower reinfusion rates may reduce the DIC risk, but this remains investigational.
Why the Denver Shunt Became a Niche Device
Through the 1980s, peritoneovenous shunts were a mainstay for refractory ascites. Their decline was driven by several converging factors. TIPS, introduced in the early 1990s, offered a way to treat the underlying portal hypertension rather than just divert its downstream product, and accumulating trial data showed its longer-term superiority. Liver transplantation expanded access for many of the cirrhosis patients who would previously have been managed with palliative shunting. And serial large-volume paracentesis, while labor-intensive, turned out to be surprisingly safe and well-tolerated for many patients, with albumin infusions helping to offset the protein loss that had been one of the strongest arguments for shunting in the first place.
The complications profile also took its toll on the shunt’s reputation. DIC, even at relatively low incidence, is a frightening complication for clinicians. High rates of shunt occlusion meant the problem was often just deferred rather than solved. And the availability of TIPS gave hepatologists a procedure they could manage within their own specialty rather than referring to surgery.
None of this means the Denver shunt is obsolete. It occupies a defined space: patients with refractory ascites who cannot get a TIPS (due to portal vein clotting, severe hepatic encephalopathy risk, or non-portal-hypertensive causes of ascites), who are not candidates for liver transplantation, and who find repeated paracentesis too burdensome to sustain. For cancer patients with malignant ascites, where TIPS is not relevant and the goal is quality of life over weeks to months, the Denver shunt can be one of the more effective palliative interventions available.